[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1121350T1 - Απο του στοματος φαρμακοτεχνικες μορφες αναλογων κυτιδινης και μεθοδοι χρησης αυτων - Google Patents

Απο του στοματος φαρμακοτεχνικες μορφες αναλογων κυτιδινης και μεθοδοι χρησης αυτων

Info

Publication number
CY1121350T1
CY1121350T1 CY20191100231T CY191100231T CY1121350T1 CY 1121350 T1 CY1121350 T1 CY 1121350T1 CY 20191100231 T CY20191100231 T CY 20191100231T CY 191100231 T CY191100231 T CY 191100231T CY 1121350 T1 CY1121350 T1 CY 1121350T1
Authority
CY
Cyprus
Prior art keywords
methods
oral pharmaceutical
pharmaceutical forms
cytidine analogs
cytidine
Prior art date
Application number
CY20191100231T
Other languages
English (en)
Inventor
Jeffrey B. Etter
Mei Lai
Jay Thomas Backstrom
Original Assignee
Celgene Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40941609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121350(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corporation filed Critical Celgene Corporation
Publication of CY1121350T1 publication Critical patent/CY1121350T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα αποκάλυψη παρέχει φαρμακευτικές συνθέσεις που περιλαμβάνουν ανάλογα κυτιδίνης για από του στόματος χορήγηση, όπου οι συνθέσεις απελευθερώνουν το ανάλογο κυτιδίνης ουσιαστικά στο στομάχι. Επίσης παρέχονται μέθοδοι θεραπείας ασθενειών και διαταραχών που χρησιμοποιούν τις από του στόματος φαρμακοτεχνικές μορφές που παρέχονται στο παρόν.
CY20191100231T 2008-05-15 2019-02-25 Απο του στοματος φαρμακοτεχνικες μορφες αναλογων κυτιδινης και μεθοδοι χρησης αυτων CY1121350T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5360908P 2008-05-15 2008-05-15
US20114508P 2008-12-05 2008-12-05
US15787509P 2009-03-05 2009-03-05
PCT/US2009/002999 WO2009139888A1 (en) 2008-05-15 2009-05-14 Oral formulations of cytidine analogs and methods of use thereof

Publications (1)

Publication Number Publication Date
CY1121350T1 true CY1121350T1 (el) 2020-05-29

Family

ID=40941609

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20191100231T CY1121350T1 (el) 2008-05-15 2019-02-25 Απο του στοματος φαρμακοτεχνικες μορφες αναλογων κυτιδινης και μεθοδοι χρησης αυτων
CY20201100168T CY1122681T1 (el) 2008-05-15 2020-02-24 Απο του στοματος σκευασματα αναλογων κυτιδινης και μεθοδοι χρησης αυτων
CY20211100917T CY1124720T1 (el) 2008-05-15 2021-10-20 Απο του στοματος σκευασματα αναλογων κυτιδινης και μεθοδοι χρησης αυτων

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20201100168T CY1122681T1 (el) 2008-05-15 2020-02-24 Απο του στοματος σκευασματα αναλογων κυτιδινης και μεθοδοι χρησης αυτων
CY20211100917T CY1124720T1 (el) 2008-05-15 2021-10-20 Απο του στοματος σκευασματα αναλογων κυτιδινης και μεθοδοι χρησης αυτων

Country Status (34)

Country Link
US (11) US8846628B2 (el)
EP (6) EP2695609B1 (el)
JP (3) JP2011520880A (el)
KR (1) KR101633134B1 (el)
CN (3) CN103479586B (el)
AR (1) AR071808A1 (el)
AU (3) AU2009246926B2 (el)
BR (1) BRPI0912717A2 (el)
CA (3) CA2761582C (el)
CL (2) CL2009001170A1 (el)
CO (1) CO6300930A2 (el)
CR (1) CR11789A (el)
CY (3) CY1121350T1 (el)
DK (5) DK3692983T3 (el)
EC (1) ECSP10010665A (el)
ES (5) ES2774226T3 (el)
FI (1) FI3782612T3 (el)
HR (5) HRP20221064T1 (el)
HU (5) HUE059635T2 (el)
IL (2) IL238087B (el)
LT (5) LT3782612T (el)
MX (2) MX2010012470A (el)
MY (1) MY161593A (el)
NI (1) NI201000193A (el)
NZ (3) NZ589437A (el)
PE (2) PE20091971A1 (el)
PL (5) PL2299984T3 (el)
PT (5) PT3692983T (el)
RU (3) RU2476207C2 (el)
SG (1) SG193206A1 (el)
SI (5) SI2695609T1 (el)
TW (3) TWI522103B (el)
WO (1) WO2009139888A1 (el)
ZA (1) ZA201008229B (el)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US8497292B2 (en) * 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
EP2211870A1 (en) * 2007-11-01 2010-08-04 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
US20150290228A1 (en) * 2008-05-15 2015-10-15 Jay T. BACKSTROM Oral formulations of cytidine analogs and methods of use thereof
PL2299984T3 (pl) 2008-05-15 2019-07-31 Celgene Corporation Doustne formulacje analogów cytydyny i sposoby ich zastosowania
CA2789365A1 (en) 2009-02-10 2010-08-19 Celgene International Sarl Methods for treating non-small cell lung cancer using 5-azacytidine
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
US8759303B2 (en) 2010-06-07 2014-06-24 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
US20110301102A1 (en) * 2010-06-07 2011-12-08 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
MY166014A (en) * 2010-06-07 2018-05-21 Abraxis Bioscience Llc Combination therapy methods for treating proliferative diseases
CN103338753A (zh) 2011-01-31 2013-10-02 细胞基因公司 胞苷类似物的药物组合物及其使用方法
EP2481813A1 (en) * 2011-02-01 2012-08-01 Centro di Riferimento Oncologico - Istituto Nazionale Tumori - Aviano Markers of cutaneous melanoma and uses thereof
RU2013148580A (ru) 2011-03-31 2015-05-10 Селджин Интернешнл Сарл Синтез 5-азацитидина
MX2014005314A (es) * 2011-11-01 2014-09-08 Celgene Corp Metodos para tratar canceres utilizando formulaciones orales de analogos de citidina.
JP6231988B2 (ja) 2011-11-03 2017-11-15 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｎｅｄｄ８活性化酵素阻害剤および低メチル化剤の投与
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2014015153A2 (en) * 2012-07-20 2014-01-23 Star Biotechnology, Llc Compositions and methods for treating ewing's sarcoma and other disorders related to ews-fli1
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
EA036325B1 (ru) 2014-03-14 2020-10-27 Аджиос Фармасьютикалз, Инк. Фармацевтическая композиция на основе твердой дисперсии ингибитора idh1
WO2015195634A1 (en) 2014-06-17 2015-12-23 Celgne Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
EP3182996B1 (en) 2014-08-22 2022-12-28 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
CA2986522A1 (en) * 2015-05-22 2016-12-01 Novartis Ag Pharmaceutical compositions
SG11201803091PA (en) 2015-10-15 2018-05-30 Agios Pharmaceuticals Inc Combination therapy for treating malignancies
WO2017066611A1 (en) * 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
ES2981538T3 (es) 2015-10-15 2024-10-09 Servier Lab Terapia de combinación que comprende ivosidenib, citarabina y daunorrubicina o idarrubicina para el tratamiento de leucemia mielógena aguda
MX2021007569A (es) 2015-12-03 2022-06-09 Epidestiny Inc Composiciones que contienen decitabina, 5azacitidina y tetrahidrouridina y sus usos.
WO2017180489A1 (en) 2016-04-12 2017-10-19 The Johns Hopkins University Quantitative determination of nucleoside analogue drugs in genomic dna or rna
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
EA039874B1 (ru) * 2019-06-06 2022-03-22 Общество С Ограниченной Ответственностью "Технология Лекарств" Композиция помалидомида для лечения заболеваний, ассоциированных с фактором некроза опухоли (фно)
US20220249528A1 (en) * 2019-06-20 2022-08-11 Celgene Corporation Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
JP2022553306A (ja) 2019-10-21 2022-12-22 ノバルティス アーゲー Ｔｉｍ－３阻害剤およびその使用
BR112022007376A2 (pt) 2019-10-21 2022-07-05 Novartis Ag Terapias de combinação com venetoclax e inibidores de tim-3
IL293834A (en) 2019-12-20 2022-08-01 Novartis Ag A combination of anti-tim-3 antibody mbg453 and anti, nis793 tgf-beta antibody with or without decitabine or anti-pd-1 antibody spratlizumab, for the treatment of myelofibrosis and myelodysplastic syndrome
EP4090335A1 (en) 2020-01-17 2022-11-23 Novartis AG Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
EP4185583A4 (en) 2020-07-23 2024-10-30 Southern Res Inst POLYMORPHS OF 5-AZA-4'-THIO-2'-DEOXYCYTIDINE
EP4262812A1 (en) 2020-12-18 2023-10-25 Southern Research Institute 6-aza-nucleoside prodrugs as antiviral agents for treating virus infections
WO2022192621A1 (en) 2021-03-12 2022-09-15 Celgene Corporation Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles
CA3236051A1 (en) 2021-10-19 2023-04-27 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2913408A (en) 1956-12-28 1959-11-17 Dow Chemical Co Corrosion inhibitors for ferrous metals in aqueous solutions of non-oxidizing acids
GB1050899A (el) * 1963-12-22
CH527207A (de) 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
CH507969A (de) 1968-11-12 1971-05-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de) * 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
FR2123632A6 (en) 1971-01-26 1972-09-15 Ceskoslovenska Akademie Ved Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine
DE2122991C2 (de) * 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
DE2508312A1 (de) * 1975-02-24 1976-09-02 Schering Ag Neues verfahren zur herstellung von nucleosiden
DE2757365A1 (de) * 1977-12-20 1979-06-21 Schering Ag Neues verfahren zur herstellung von nucleosiden
JPS59151784U (ja) 1983-03-30 1984-10-11 日産自動車株式会社 トラツクのリヤボデイ構造
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
EP0397042B1 (de) 1989-05-10 1995-08-16 F. Hoffmann-La Roche Ag Herstellung von Isochinolinderivaten
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US6432924B1 (en) * 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
GB9412394D0 (en) * 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US5700640A (en) * 1994-09-16 1997-12-23 Basf Aktiengesellschaft Inducers of gamma globin gene expression and screening assays therefor
US5539209A (en) 1994-10-17 1996-07-23 Trojan Technologies Inc. Method of cleaning fouling materials from a radiation module
EP1027359B9 (en) * 1996-10-16 2003-09-17 Ribapharm, Inc. Monocyclic l-nucleosides, analogs and uses thereof
CA2290624C (en) 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) * 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6566395B1 (en) 1999-05-25 2003-05-20 Biomedicines, Inc. Methods of treating proliferative disorders
US6803195B1 (en) 1999-07-02 2004-10-12 Ramot At Tel-Aviv University Ltd. Facile detection of cancer and cancer risk based on level of coordination between alleles
AU6015400A (en) * 1999-07-16 2001-02-05 Amato Pharmaceutical Products, Ltd. Glycyrrhizin preparations for transmucosal absorption
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ATE340563T1 (de) 2000-02-04 2006-10-15 Depomed Inc DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
EP1399159A4 (en) 2001-06-01 2007-02-14 Cytovia Inc 4-SUBSTITUTE-1- (ARYLMETHYLIDENE) THIOSEMICARBAZIDE, 4-SUBSTITUTE-1- (ARYLCARBONYL) THIOSEMICARBAZIDE AND ANALOGUES AS ACTIVATORS OF APOPTOSIS CAPSASES AND TRIGS, AND USE THEREOF
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030220254A1 (en) * 2002-03-29 2003-11-27 Texas Tech University System Composition and method for preparation of an oral dual controlled release formulation of a protein and inhibitor
AU2003278904A1 (en) * 2002-09-24 2004-04-19 Kornis Pharmaceuticals, Incorporated 1, 3, 5-triazines for treatment of viral diseases
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
WO2004041195A2 (en) 2002-10-31 2004-05-21 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
US7144876B2 (en) 2002-12-18 2006-12-05 Cytovia, Inc. 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
US7038038B2 (en) * 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
AU2004241729A1 (en) 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents
EP2226072A1 (en) * 2003-08-29 2010-09-08 Aton Pharma, Inc. Combinations of suberoylanilide hydroxamic acid and antimetbolic agents for treating cancer
US7192781B2 (en) * 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
US20060069060A1 (en) * 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
CN100374160C (zh) * 2004-11-22 2008-03-12 山东蓝金生物工程有限公司 一种含抗代谢类药物的抗癌药物组合物
US20060128654A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
EP3698783A1 (en) 2005-02-18 2020-08-26 Abraxis BioScience, LLC Combinations and modes of administration of therapeutic agents and combination therapy
SI1868579T1 (sl) 2005-03-07 2011-02-28 Bayer Schering Pharma Ag Farmacevtski sestavek, ki obsega omega-karboksiarilno substituirano difenil sečnino, za zdravljenje raka
CN100500212C (zh) * 2005-04-06 2009-06-17 山东蓝金生物工程有限公司 一种抗实体肿瘤药物组合物
US8058260B2 (en) * 2006-05-22 2011-11-15 Xenoport, Inc. 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
WO2008028193A2 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
US7759481B2 (en) * 2007-01-11 2010-07-20 Ivax Corporation Solid state forms of 5-azacytidine and processes for preparation thereof
EP2114152A1 (en) 2007-01-25 2009-11-11 Nevada Cancer Institute Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents
JP5173298B2 (ja) 2007-07-25 2013-04-03 キヤノン株式会社 プリント配線板およびそれを用いた電子機器
WO2009016617A2 (en) 2007-08-02 2009-02-05 Chemagis Ltd. Stable highly pure azacitidine and preparation methods therefor
UA99308C2 (ru) 2007-09-26 2012-08-10 Маунт Синай Скул Оф Медсин Аналог азацитидина и его применение
EP2048151A1 (en) * 2007-10-10 2009-04-15 Cilag AG Method for producing nucleosides by direct glycosylation of the nucleoside base
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain vehicles, installations and methods
EP2211870A1 (en) * 2007-11-01 2010-08-04 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
PL2299984T3 (pl) 2008-05-15 2019-07-31 Celgene Corporation Doustne formulacje analogów cytydyny i sposoby ich zastosowania
WO2010014883A2 (en) * 2008-08-01 2010-02-04 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
EP2324042B1 (en) * 2008-08-06 2012-11-28 Sicor, Inc. Process for preparing azacytidine intermediate
JP5650643B2 (ja) * 2008-08-08 2015-01-07 サイノファーム タイワン リミテッド ５−アザシトシンヌクレオシド及びその誘導体の製造方法
KR101807319B1 (ko) 2008-11-22 2017-12-11 제넨테크, 인크. 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도
US20110042247A1 (en) * 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
WO2011014541A1 (en) 2009-07-30 2011-02-03 Eagle Pharmaceuticals, Inc. Stable formulations of azacitidine
IT1399195B1 (it) * 2010-03-30 2013-04-11 Chemi Spa Processo per la sintesi di azacitidina e decitabina
CN103338753A (zh) * 2011-01-31 2013-10-02 细胞基因公司 胞苷类似物的药物组合物及其使用方法
RU2013148580A (ru) 2011-03-31 2015-05-10 Селджин Интернешнл Сарл Синтез 5-азацитидина
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
MX2014005314A (es) * 2011-11-01 2014-09-08 Celgene Corp Metodos para tratar canceres utilizando formulaciones orales de analogos de citidina.

Also Published As

Publication number Publication date
HRP20231439T1 (hr) 2024-03-01
CA2761582C (en) 2022-06-07
HRP20190100T1 (hr) 2019-04-05
CA3094590A1 (en) 2009-11-19
SI3692983T1 (sl) 2021-11-30
US8846628B2 (en) 2014-09-30
RU2765076C2 (ru) 2022-01-25
RU2018109222A3 (el) 2021-07-02
LT3782611T (lt) 2022-10-10
JP2015110575A (ja) 2015-06-18
CO6300930A2 (es) 2011-07-21
US20150374732A1 (en) 2015-12-31
EP3782612B1 (en) 2023-11-08
US20200316099A1 (en) 2020-10-08
AU2009246926B2 (en) 2014-06-26
HRP20221064T1 (hr) 2022-11-11
TW201006478A (en) 2010-02-16
PL3782612T3 (pl) 2024-03-04
SG193206A1 (en) 2013-09-30
EP3782612A1 (en) 2021-02-24
US10463683B2 (en) 2019-11-05
JP2011520880A (ja) 2011-07-21
PL3782611T3 (pl) 2022-11-07
US20180153916A1 (en) 2018-06-07
PL2695609T3 (pl) 2020-05-18
EP2299984B1 (en) 2018-11-28
ES2774226T3 (es) 2020-07-17
IL209307A0 (en) 2011-01-31
LT2299984T (lt) 2019-03-25
MY161593A (en) 2017-04-28
AU2015202884B2 (en) 2017-02-23
CR11789A (es) 2011-02-21
EP3782611B1 (en) 2022-07-06
ES2969144T3 (es) 2024-05-16
EP4327888A2 (en) 2024-02-28
IL209307A (en) 2016-02-29
HUE059635T2 (hu) 2022-12-28
MX2010012470A (es) 2010-12-02
CL2009001170A1 (es) 2010-06-04
US20220079964A1 (en) 2022-03-17
NZ589437A (en) 2012-11-30
US20090286752A1 (en) 2009-11-19
US20220105118A1 (en) 2022-04-07
AU2009246926A1 (en) 2009-11-19
TWI522103B (zh) 2016-02-21
US12053482B2 (en) 2024-08-06
HUE064677T2 (hu) 2024-04-28
ECSP10010665A (es) 2011-01-31
US20200101095A1 (en) 2020-04-02
CY1124720T1 (el) 2022-07-22
CN103479586B (zh) 2017-03-01
CN102099018B (zh) 2016-01-13
CN102099018A (zh) 2011-06-15
TWI618538B (zh) 2018-03-21
JP2017137326A (ja) 2017-08-10
RU2012147739A (ru) 2014-05-20
EP4327888A3 (en) 2024-05-22
LT3692983T (lt) 2021-11-10
EP3692983B1 (en) 2021-08-11
IL238087B (en) 2019-01-31
CA3094580C (en) 2021-05-18
NZ602833A (en) 2014-04-30
US20230255996A1 (en) 2023-08-17
EP3692983A1 (en) 2020-08-12
PT2695609T (pt) 2020-03-02
PL3692983T3 (pl) 2021-12-27
PT3692983T (pt) 2021-11-08
US10646503B2 (en) 2020-05-12
EP2299984A1 (en) 2011-03-30
AU2013202665B2 (en) 2015-06-25
DK2695609T3 (da) 2020-02-10
CY1122681T1 (el) 2020-10-14
LT2695609T (lt) 2020-02-10
EP3782611A1 (en) 2021-02-24
PL2299984T3 (pl) 2019-07-31
ES2893785T3 (es) 2022-02-10
PT3782611T (pt) 2022-11-18
CL2013001097A1 (es) 2013-11-29
TW201729817A (zh) 2017-09-01
EP2695609B1 (en) 2019-12-11
CA2761582A1 (en) 2009-11-19
SI3782611T1 (sl) 2022-10-28
CN103479586A (zh) 2014-01-01
TW201513869A (zh) 2015-04-16
NI201000193A (es) 2011-08-01
HRP20211398T1 (hr) 2021-12-10
US11571436B2 (en) 2023-02-07
BRPI0912717A2 (pt) 2014-12-23
DK2299984T3 (en) 2019-03-04
MX363023B (es) 2019-03-05
AR071808A1 (es) 2010-07-14
CN105535008A (zh) 2016-05-04
JP6426778B2 (ja) 2018-11-21
JP6105547B2 (ja) 2017-03-29
PE20142440A1 (es) 2015-01-28
US20230241086A1 (en) 2023-08-03
DK3782612T3 (da) 2024-01-15
SI3782612T1 (sl) 2024-02-29
ZA201008229B (en) 2012-02-29
HUE047707T2 (hu) 2020-05-28
DK3692983T3 (da) 2021-09-20
ES2712506T3 (es) 2019-05-13
SI2299984T1 (sl) 2019-04-30
DK3782611T3 (da) 2022-09-05
HUE042825T2 (hu) 2019-07-29
KR20110015629A (ko) 2011-02-16
US10220050B2 (en) 2019-03-05
PT2299984T (pt) 2019-02-25
EP2695609A1 (en) 2014-02-12
SI2695609T1 (sl) 2020-03-31
HUE055911T2 (hu) 2021-12-28
CA3094580A1 (en) 2009-11-19
ES2927556T3 (es) 2022-11-08
AU2015202884A1 (en) 2015-06-18
LT3782612T (lt) 2023-12-27
RU2010151428A (ru) 2012-06-20
AU2013202665A1 (en) 2013-05-02
US20150056280A1 (en) 2015-02-26
HRP20200096T1 (hr) 2020-04-03
WO2009139888A1 (en) 2009-11-19
RU2018109222A (ru) 2019-09-17
RU2476207C2 (ru) 2013-02-27
KR101633134B1 (ko) 2016-06-23
NZ623495A (en) 2015-08-28
PT3782612T (pt) 2024-01-18
US20190231803A1 (en) 2019-08-01
PE20091971A1 (es) 2010-01-15
FI3782612T3 (fi) 2024-01-16

Similar Documents

Publication Publication Date Title
CY1121350T1 (el) Απο του στοματος φαρμακοτεχνικες μορφες αναλογων κυτιδινης και μεθοδοι χρησης αυτων
CY1121593T1 (el) Προφαρμακα της τετραϋδροκανναβινολης, συνθεσεις οι οποιες περιλαμβανουν προφαρμακα της τετραϋδροκανναβινολης και μεθοδοι χρησης των ιδιων
CY1123050T1 (el) Φαρμακα ινδολιδονης για την θεραπεια ή προληψη ινωτικων ασθενειων
CY1122786T1 (el) Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
CY1118956T1 (el) Νεες θεραπευτικες προσεγγισεις για τη θεραπευτικη αντιμετωπιση της νοσου alzheimer και των συγγενων διαταραχων μεσω διαμορφωσης της αγγειογενεσης
CY1118017T1 (el) Υποβαλλοντας σε αγωγη την ανεπαρκεια και το ελλειμμα βιταμινης d με 25-υδροξυβιταμινη d2 και 25-υδροξυβιταμινη d3
CY1118731T1 (el) Φαρμακευτικες συνθεσεις αλβιγλουτιδης
CY1117237T1 (el) Συνθεσεις σταθερων τιακουμυκινων
CY1118179T1 (el) Φαρμακευτικη συνθεση
MX2018011278A (es) Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina.
CY1117584T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1
CY1117995T1 (el) Δευτεριωμενα παραγωγα κατεχολαμινης και φαρμακα που περιεχουν τις εν λογω ενωσεις
CY1110824T1 (el) Διασπεipoμενη στο στομα φαρμακευτικη συνθεση για απο του στοματος, μεσω του στοματικου βλεννογονου ή υπογλωσσια χορηγηση αγομελατινης
NO20076508L (no) Acyloksykarbamat prodroger av traneksaminsyre og fremgangsmater for fremstilling og anvendelse derav
CY1111977T1 (el) Παραγωγα πιπεριδιν-4-υλ-πυριδαζιν-3-υλαμινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
UY32487A (es) Composiciones farmacéuticas de liberación inmediata comprendiendo oxicodona y naloxona
UY29639A1 (es) Amidas sustituidas con heteroarilo que comprenden un grupo enlazador insaturado o cíclico, y su uso como productos farmacéuticos
CY1108324T1 (el) Νεοι τεταρτοταγοποιημενοι εστερες κουινουκλιδινης
CY1113759T1 (el) Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
CY1115556T1 (el) Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη
CY1116759T1 (el) Ανθελονοσιακη φαρμακευτικη συνθεση
TR201821157T4 (tr) İbandroni̇k asi̇t veya bunun farmasöti̇k olarak kabul edi̇lebi̇li̇r bi̇r tuzu ve d vi̇tami̇ni̇ i̇çeren oral uygulamaya yöneli̇k kati bi̇leşi̇m.
CY1112227T1 (el) Πιπεριδινυλαμινο-πυριδαζινες και η χρηση τους ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
MX367327B (es) Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos.